AIPSN urges govt to reconsider emergency approval for Covaxin till Phase 3 data is published
AIPSN urges govt to rethink emergency approval for Covaxin until Part 3 information is printed Both pausing or cancelling approvals isn’t extraordinary, and the CDSCO does have the authority to take action. An illustration of COVAXIN, the vaccine candidate for COVID-19 developed by Bharath Biotech. Picture: Bharath Biotech With two COVID-19 vaccines – Serum Institute… Read More »